Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Fehse, Boris  [Clear All Filters]
2013
Jung G, Sun J, Petrowitz B, Riecken K, Kruszewski K, Jankowiak W, Kunst F, Skevas C, Richard G, Fehse B, et al. Genetically Modified Neural Stem Cells for a Local and Sustained Delivery of Neuroprotective Factors to the Dystrophic Mouse Retina. Stem Cells Transl Med. 2013.
Zhan H, Gilmour K, Chan L, Farzaneh F, McNicol AMarie, Xu J-H, Adams S, Fehse B, Veys P, Thrasher A, et al. Production and First-in-Man Use of T Cells Engineered to Express a HSVTK-CD34 Sort-Suicide Gene. PLoS One. 2013;8(10):e77106.
2014
Stübig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder TMC, Fehse B, Kröger N. 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm. 2014;2014:418292.
Triviai I, Ziegler M, Bergholz U, Oler AJ, Stübig T, Prassolov V, Fehse B, Kozak CA, Kröger N, Stocking C. Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis. Proc Natl Acad Sci U S A. 2014.
Gomez-Nicola D, Riecken K, Fehse B, V Perry H. In-vivo RGB marking and multicolour single-cell tracking in the adult brain. Sci Rep. 2014;4:7520.
2015
Triviai I, Stübig T, Niebuhr B, Hussein K, Tsiftsoglou A, Fehse B, Stocking C, Kröger N. CD133 marks a stem cell population that drives human Primary Myelofibrosis. Haematologica. 2015.
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger JS, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, et al. Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget. 2015;6(8):6341-6358.
Stahl T, Böhme M, Kröger N, Fehse B. Digital PCR to assess haematopoietic chimaerism after allogeneic stem cell transplantation. Exp Hematol. 2015.
Nikitenko NA, Speiseder T, Groitl P, Spirin PV, Prokofjeva MM, Lebedev TD, Rubtsov PM, Lam E, Riecken K, Fehse B, et al. Targeting species D adenoviruses replication to counteract the epidemic keratoconjunctivitis. Biochimie. 2015.
2016
Hossain JA, Ystaas LRømo, Mrdalj J, Välk K, Riecken K, Fehse B, Bjerkvig R, Grønli J, Miletic H. Lentiviral HSV-Tk.007 mediated suicide gene therapy is not toxic for normal brain cells. J Gene Med. 2016.
Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuk F. Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins. Oncotarget. 2016.
2018
Roh V, Abramowski P, Hiou-Feige A, Cornils K, Rivals J-P, Zougman A, Aranyossy T, Thielecke L, Truan Z, Mermod M, et al. Cellular Barcoding Identifies Clonal Substitution as a Hallmark of Local Recurrence in a Surgical Model of Head and Neck Squamous Cell Carcinoma. Cell Rep. 2018;25(8):2208-2222.e7.
2021
Schambach A, Morgan M, Fehse B. Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy. Mol Ther. 2021.
2022
Schwarze LIsabell, Głów D, Sonntag T, Uhde A, Fehse B. Correction: Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application. Gene Ther. 2022.
2023
Grochowska KM, Sperveslage M, Raman R, Failla AV, Głów D, Schulze C, Laprell L, Fehse B, Kreutz MR. Chaperone-mediated autophagy in neuronal dendrites utilizes activity-dependent lysosomal exocytosis for protein disposal. Cell Rep. 2023;42(8):112998.
Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, Ayuk F, Fehse B, Kröger N. Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation. Hemasphere. 2023;7(7):e921.
Zecher BF, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick ME, Yuki Y, Martin MP, Glow D, Schröder-Schwarz J, et al. is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells. Gut. 2023.
Luther M, Henes FOliver, Zabelina T, Massoud R, Janson D, Wolschke C, Klyuchnikov E, Gagelmann N, Fehse B, Adam G, et al. Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2023.
2024
Seifert L, Riecken K, Zahner G, Hambach J, Hagenstein J, Dubberke G, Huber TB, Koch-Nolte F, Fehse B, Tomas NM. An antigen-specific chimeric autoantibody receptor NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells. Kidney Int. 2024.
Ayuk F, Fehse B. CARs come to AID. Mol Ther. 2024.
Fischbach F, Richter J, Pfeffer LKristina, Fehse B, Berger SCarolina, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024.
Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, Fehse B, Bacher U, Kröger N. Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia. 2024.